Next Article in Journal
Quality and In Vivo Assessment of a Fulvic Acid Complex: A Validation Study
Next Article in Special Issue
Ex Vivo and In Vivo Study of Some Isoquinoline Precursors
Previous Article in Journal
Antifungal and Modulatory Activity of Lemon Balm (Lippia alba (MILL.) N. E. BROWN) Essential Oil
Previous Article in Special Issue
Gossypol from Gossypium spp. Inhibits Helicobacter pylori Clinical Strains and Urease Enzyme Activity: Bioactivity and Safety Assessments
Article

Comparison of the Purity and Impurity of Glucagon-for-Injection Products under Various Stability Conditions

Amphastar Pharmaceuticals, Inc., 11570 6th Street, Rancho Cucamonga, CA 91730, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Susi Burgalassi
Sci. Pharm. 2022, 90(2), 32; https://doi.org/10.3390/scipharm90020032
Received: 31 March 2022 / Revised: 29 April 2022 / Accepted: 11 May 2022 / Published: 17 May 2022
(This article belongs to the Special Issue Feature Papers in Scientia Pharmaceutica)
Glucagon is a polypeptide hormone that serves as an essential therapeutic agent in the emergency treatment of hypoglycemia. Recently, the first generic glucagon for injection was approved. However, unlike its brand name counterpart, which is produced via recombinant DNA, the generic glucagon is produced using a chemical synthesis method. Regardless of its origin, impurities may occur in both glucagon drug products. While these impurities may greatly compromise the safety and efficacy of the glucagon drug products, studies accessing the impurities of glucagon for injection are limited. This manuscript analyzed the stability and impurities of a generic and brand glucagon for injection, including desamido and non-desamido impurities, under various storage and temperature conditions using an ultra-performance liquid chromatography method. The glucagon products were analyzed after 6 and 24 months of storage under room temperatures (20–25 °C). In addition, the products were also assessed after 6 months of storage under high temperatures (40 °C). Under each stability storage condition, three lots of the synthetic glucagon were evaluated by UPLC with at least one lot of the recombinant glucagon for comparison. A total of 37 peaks were identified (except for the solvent peaks, which appeared at retention times less than 1.5 min) from the synthetic and recombinant glucagon lots. It was found that the number of impurities observed in the synthetic glucagon were lower than the referenced recombinant glucagon across all stability conditions. Throughout all tested conditions, the synthetic glucagon for injection had an averaged purity of 92.8–99.3%, while the referenced recombinant drug had an averaged purity of 70.3–91.7%. Based on the study results, it can be concluded that the impurity profile for the synthetic glucagon for injection has a comparable and even lower level of impurities than the recombinant version under all stability conditions. View Full-Text
Keywords: glucagon; HPLC; impurity; stability; synthetic peptide; recombinant; injection glucagon; HPLC; impurity; stability; synthetic peptide; recombinant; injection
Show Figures

Figure 1

MDPI and ACS Style

Bao, Z.; Cheng, Y.-C.; Luo, M.Z.; Zhang, J.Y. Comparison of the Purity and Impurity of Glucagon-for-Injection Products under Various Stability Conditions. Sci. Pharm. 2022, 90, 32. https://doi.org/10.3390/scipharm90020032

AMA Style

Bao Z, Cheng Y-C, Luo MZ, Zhang JY. Comparison of the Purity and Impurity of Glucagon-for-Injection Products under Various Stability Conditions. Scientia Pharmaceutica. 2022; 90(2):32. https://doi.org/10.3390/scipharm90020032

Chicago/Turabian Style

Bao, Zhongli, Ya-Chi Cheng, Mary Z. Luo, and Jack Y. Zhang. 2022. "Comparison of the Purity and Impurity of Glucagon-for-Injection Products under Various Stability Conditions" Scientia Pharmaceutica 90, no. 2: 32. https://doi.org/10.3390/scipharm90020032

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop